Bell's palsy
Conditions
Interventions
experimental group:Basic Western Medicine + Acupuncture & Electroacupuncture
control group:Basic Western Medicine + Comfort Needle & False Electroacupuncture
Sponsors
The Third Affiliated Hospital of Beijing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: (1) Comply with the clinical diagnostic criteria of facial nerve paralysis in the Chinese Guidelines for Diagnosis and Treatment of Idiopathic Facial Nerve Palsy issued by the Neurology Section of the Chinese Medical Association and other organizations in 2016 and the TCM diagnostic criteria of facial paralysis in the Acupuncture and Moxibustion Therapeutics issued by China Traditional Chinese Medicine Publishing House in 2021; (2) Age 18-60 years old gender is not limited; (3) Patients with severe Bell's palsy. (Definition of severe Bell's palsy: Bell's palsy mild moderate and severe grades are mainly based on different facial evaluation scales referring to Lancet Neurology's description of severe Bell's palsy and based on the diagnosis of Bell's palsy the House-Brackmann facial nerve function grades in V-VI were met Sunnybrook Facial Nerve Rating Scale = 25 was defined as severe Bell's palsy.) (4) Duration of disease within one week (onset = 7 days); (5) Signed informed consent.
Exclusion criteria
Exclusion criteria: (1) Facial nerve palsy due to Hunter syndrome and other identified disease causes such as Guillain-Barré syndrome multiple sclerosis tuberculosis Mobius syndrome diabetic peripheral neuropathies encephalitis (fungal viral bacterial) human immunodeficiency virus infections Lyme disease otitis media herpes zoster virus infections syphilis brainstem strokes tumors of the facial nerve cutaneous tumors tumors of the parotid gland and facial nerve trauma etc; (2) Combined with serious diseases of cardiovascular cerebrovascular hepatic renal and hematopoietic systems; (3) Suffering from serious mental illness and incapable of behavior; (4) Coagulation disorders; (5) Pregnant and lactating women; (6) Acute local skin infections; and (7) Those who cannot tolerate this treatment plan (e.g. needle dizziness fear of needles etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients with House-Brackmann Facial Nerve Function Rating Scale (H-B rating) scores of grade II and below; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time required for the face to regain mild and normal function (time required for H-B rating of II and below);nerve growth factor;House-Brackmann Facial Nerve Function Rating Scale (H-B rating);Sunnybrook Facial Nerve Rating Scale;Facial Disability Index (FDI);glial cell line-derived neurotrophic factor; | — |
Countries
China
Contacts
Public ContactBai Peng
The Third Affiliated Hospital of Beijing University of Chinese Medicine
Outcome results
None listed